Myostatin regulates tissue potency and cardiac calcium-Handling proteins

Endocrinology

Volumn 155, Issue 5, 2014, Pages 1771-1785

  Jackson, Melissa F ^a   Li, Naisi ^a   Rodgers, Buel D ^a,b  

^a Center for Reproductive Biology   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; DOXYCYCLINE; FAT; GREEN FLUORESCENT PROTEIN; HISTONE H2B; MYOSTATIN; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOFLUORESCENCE; BODY WEIGHT; BONE DENSITY; BONE LENGTH; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; EPICARDIUM; GASTROCNEMIUS MUSCLE; GENOTYPE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HISTOLOGY; LABEL RETAINING CELL; LIPID STORAGE; MOUSE; MUSCLE DEVELOPMENT; MUSCLE GROWTH; NEWBORN; NONHUMAN; OBESITY; ORGAN WEIGHT; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SATELLITE CELL; SKELETAL MUSCLE; SLOW CYCLING STEM CELL; STEM CELL; TIBIA; TISSUE DISTRIBUTION; TRANSIT AMPLIFYING CELL; WILD TYPE;

ADIPOGENESIS; ANIMALS; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CROSSES, GENETIC; FEMALE; GREEN FLUORESCENT PROTEINS; HISTONES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE DEVELOPMENT; MUTANT PROTEINS; MYOCARDIUM; MYOSTATIN; OSTEOGENESIS; RECOMBINANT FUSION PROTEINS; SEX CHARACTERISTICS; STEM CELLS;

EID: 84899454477     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-2014     Document Type: Article

References (81)

1. Rodgers BD, Garikipati DK. Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocr Rev. 2008; 29(5):513-534.
2. Sharma M, Kambadur R, Matthews KG, et al. Myostatin, a transforming growth factor-ß superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol. 1999;180(1):1-9.
3. Kubota K, Sato F, Aramaki S, Soh T, Yamauchi N, Hattori MA. Ubiquitous expression of myostatin in chicken embryonic tissues: its high expression in testis and ovary. Comp Biochem Physiol A Mol Integr Physiol. 2007;148(3):550-555.
4. Amthor H, Huang R, McKinnell I, et al. The regulation and action of myostatin as a negative regulator of muscle development duringavian embryogenesis. Dev Biol. 2002;251(2):241-257.
5. østbye TK, Galloway TF, Nielsen C, Gabestad I, Bardal T, Andersen Oø. The two myostatin genes of Atlantic salmon (Salmo salar) areexpressed in a variety of tissues. Eur J Biochem. 2001;268(20): 5249-5257.
6. Jackson MF, Luong D, Vang D, et al. The aging myostatin null phenotype: cardiac hypertrophy, enhanced stress response, and sexual dimorphism. J Endocrinol. 2012;213(3):263-275.
7. Rodgers BD, Interlichia JP, GarikipatiDK,et al. Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling. J Physiol. 2009;587(Pt 20):4873-4886.
8. Artaza JN, Reisz-Porszasz S, Dow JS, et al. Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J Endocrinol. 2007; 194(1):63-76.
9. Morissette MR, Cook SA, Foo S, et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res. 2006;99(1):15-24.
10. Matsakas A, Otto A, Elashry MI, Brown SC, Patel K. Altered primary and secondary myogenesis in the myostatin-null mouse. Rejuvenation Res. 2010;13(6):717-727.
11. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-ß uperfamily member. Nature. 1997; 387(6628):83-90.
12. Elashry MI, Otto A, Matsakas A, El-Morsy SE, Patel K. Morphologyand myofiber composition of skeletal musculature of the forelimb inyoung and aged wild type and myostatin null mice. Rejuvenation Res. 2009;12(4):269-281.
13. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961;9:493-495.
14. McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol. 2003;162(6):1135-1147.
15. Wagner KR, Liu X, Chang X, Allen RE. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci USA. 2005;102(7):2519-2524.
16. Amthor H, Otto A, Vulin A, et al. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci USA. 2009;106(18):7479-7484.
17. Wang Q, McPherron AC. Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation. J Physiol. 2012;590(Pt 9):2151-2165.
18. Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev. 2013;93(1):23-67.
19. Jankowski RJ, Deasy BM, Huard J. Muscle-derived stem cells. Gene Ther. 2002;9(10):642-647.
20. Hamrick MW. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A DiscovMol Cell Evol Biol. 2003; 272A(1):388-391.
21. Hamrick MW, McPherron AC, Lovejoy CO. Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int. 2002;71(1):63-68.
22. HamrickMW,Samaddar T, Pennington C, McCormick J. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res. 2006;21(3):477-483.
23. Hamrick MW, McPherron AC, Lovejoy CO, Hudson J. Femoral morphology and cross-sectional geometry of adult myostatin-deficient mice. Bone. 2000;27(3):343-349.
24. McPherron AC, Huynh TV, Lee SJ. Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev Biol. 2009;9: 24.
25. McPherron AC, Lawler AM, Lee SJ. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet. 1999;22(3):260-264.
26. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002;109(5):595-601.
27. Lin J, Arnold HB, Della-FeraMA,Azain MJ, Hartzell DL, Baile CA. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun. 2002;291(3):701-706.
28. Akpan I, GoncalvesMD,Dhir R, et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). 2009;33(11):1265-1273.
29. Geng J, Peng F, Xiong F, et al. Inhibition of myostatin promotes myogenic differentiation of rat bone marrow-derived mesenchymal stromal cells. Cytotherapy. 2009;11(7):849-863.
30. Artaza JN, Singh R, Ferrini MG, Braga M, Tsao J, Gonzalez-Cadavid NF. Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiationinto myofibroblasts. J Endocrinol. 2008;196(2):235-249.
31. Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L, Bhasin S. Theeffects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/ß-catenin signalingpathways. J Biol Chem. 2008;283(14):9136-9145.
32. Artaza JN, Bhasin S, Magee TR, et al. Myostatin inhibits myogenesisand promotes adipogenesis inC3H10T(1/2) mesenchymal multipotent cells. Endocrinology. 2005;146(8):3547-3557.
33. Lei H, Yu B, Yang X, et al. Inhibition of adipogenic differentiation by myostatin is alleviated by arginine supplementation in porcinemuscle- derived mesenchymal stem cells. Sci China Life Sci. 2011; 54(10):908-916.
34. Dilger AC, Spurlock ME, Grant AL, Gerrard DE. Myostatin null mice respond differently to dietary-induced and genetic obesity. Anim Sci J. 2010;81(5):586-593.
35. Hamrick MW, Pennington C, Webb CN, Isales CM. Resistance to body fat gain in 'double-muscled' mice fed a high-fat diet. Int J Obes (Lond). 2006;30(5):868-870.
36. ZhouX,WangJL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531-543.
37. Khurana TS, Davies KE. Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov. 2003;2(5):379-390.
38. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 2005;19(6):543-549.
39. George I, Bish LT, Kamalakkannan G, et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail. 2010;12(5):444-453.
40. Cook SA, Matsui T, Li L, Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem. 2002;277(25): 22528-22533.
41. Pistilli EE, Bogdanovich S, Goncalves MD, et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol. 2011;178(3):1287-1297.
42. TumbarT, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. Science. 2004;303(5656):359-363.
43. Fuchs E. The tortoise and the hair: slow-cycling cells in the stem cell race. Cell. 2009;137(5):811-819.
44. Sada A, Tumbar T. New insights into mechanisms of stem cell daughter fate determination in regenerative tissues. Int Rev Cell Mol Biol. 2013;300:1-50.
45. Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science. 2010;327(5965):542-545.
46. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005;121(3):465-477.
47. Savolainen SM, Foley JF, Elmore SA. Histology atlas of the developing mouse heart with emphasis on E11.5 to E18.5. Toxicol Pathol. 2009;37(4):395-414.
48. Ruff C, Holt B, Trinkaus E. Who's afraid of the big bad Wolff?: " Wolff's law" and bone functional adaptation. Am J Phys Anthropol. 2006;129(4):484-498.
49. Robling AG. Is bone's response to mechanical signals dominated by muscle forces? Med Sci Sports Exerc. 2009;41(11):2044-2049.
50. HamrickMW,Pennington C, Byron CD. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res. 2003;21(6):1025-1032.
51. Oliver JA, Klinakis A, Cheema FH, et al. Proliferation and migration of label-retaining cells of the kidney papilla. J Am Soc Nephrol: JASN. 2009;20(11):2315-2327.
52. Roth S, Franken P, van Veelen W, et al. Generation of a tightly regulated doxycycline-inducible model for studying mouse intestinal biology. Genesis. 2009;47(1):7-13.
53. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasisand repair. Cell. 2008;135(6):1118-1129.
54. Foudi A, Hochedlinger K, Van Buren D, et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol. 2009;27(1):84-90.
55. Challen GA, Goodell MA. Promiscuous expression of H2B-GFP transgene in hematopoietic stem cells. PLoS One. 2008;3(6):e2357.
56. Bergmann O, Zdunek S, Frisen J, Bernard S, Druid H, Jovinge S. Cardiomyocyte renewal in humans. Circ Res. 2012;110(1):e17-18; author reply e19-21.
57. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. 2002;298(5601):2188-2190.
58. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102.
59. Reisz-Porszasz S, Bhasin S, Artaza JN, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab. 2003;285(4):E876-E888.
60. Kuhn EN, Wu SM. Origin of cardiac progenitor cells in the developing and postnatal heart. J Cell Physiol. 2010;225(2):321-325.
61. Sussman MA, Anversa P. Myocardial aging and senescence: where have the stem cells gone? Annu Rev Physiol. 2004;66:29-48.
62. Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006; 113(11):1451-1463.
63. Anversa P, Leri A, Kajstura J. Cardiac regeneration. J Am Coll Cardiol. 2006;47(9):1769-1776.
64. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol. 1997;92(Suppl 1):87-93.
65. Hasenfuss G, Reinecke H, Studer R, et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol. 1996;91(Suppl 2):17-22.
66. Pieske B, Maier LS, Bers DM, Hasenfuss G. Ca2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium. Circ Res. 1999;85(1):38-46.
67. del Monte F, Williams E, Lebeche D, et al. Improvement in survivaland cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001;104(12):1424-1429.
68. Loukianov E, Ji Y, Grupp IL, et al. Enhanced myocardial contractility and increased Ca2+ transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase. Circ Res. 1998;83(9):889-897.
69. Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. 2008;16(6):1026-1032.
70. Periasamy M, Kalyanasundaram A. SERCA2a gene therapy for heart failure: ready for primetime? Mol Ther. 2008;16(6):1002-1004.
71. Kemi OJ, Ceci M, Condorelli G, Smith GL, Wisloff U. Myocardial sarcoplasmic reticulum Ca2+ ATPase function is increased by aerobic interval training. Eur J Cardiovasc Prev Rehabil. 2008;15(2):145-148.
72. Cerra MC, Imbrogno S. Phospholamban and cardiac function: a comparative perspective in vertebrates. Acta Physiol (Oxf). 2012; 205(1):9-25.
73. Haghighi K, Gregory KN, Kranias EG. Sarcoplasmic reticulum Ca- ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun. 2004;322(4):1214-1222.
74. Filice E, Angelone T, De FrancescoEM,Pellegrino D, MaggioliniM, Cerra MC. Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by 17ß-estradiol in the male rat heart. Cell Physiol Biochem. 2011;28(1):41-52.
75. Feldman BJ, Streeper RS, Farese RV Jr, Yamamoto KR. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci USA. 2006;103(42):15675-15680.
76. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor ß-like signaling pathway to block adipogenesis. Mol Cell Biol. 2003;23(20): 7230-7242.
77. Hamrick MW, Shi X, Zhang W, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40(6):1544-1553.
78. Shuto T, Sarkar G, Bronk JT, Matsui N, Bolander ME. Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation. J Bone Miner Res. 1997; 12(3):403-411.
79. Elkasrawy M, Fulzele S, Bowser M, Wenger K, Hamrick M. Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression. Growth Factors. 2011;29(6):253-262.
80. Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010;10(1):56-63.
81. Williams NG, Interlichia JP, Jackson MF, Hwang D, Cohen P, Rodgers BD. Endocrine actions of myostatin: systemic regulation of the IGF and IGF binding protein axis. Endocrinology. 2011;152(1): 172-180.